Instructions for Imunofan solution 1 ml 5 ampoules
(Arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine)
English product name
Imunofan
Release Form
nasal spray. 50 ug/1 dose: fl. 40 doses with dosing device
Description Imunofan
Nasal metered spray 1 dose
arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine 50μg
40 doses - plastic bottles with metering device (1) - packs of cardboard.
ATC codes
L03AX Other immunostimulators
Clinical-pharmacological groups / Group affiliation
Immunostimulating preparation
Active substance
arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine
Pharmaco-therapeutic group Imunofan
Immunomodulatory agent
Storage Conditions
The drug is stored in a place protected from light at a temperature of 2°C to 10°C, in places inaccessible to children.
Best before date
The shelf life is 2 years. It is not recommended to use the drug after the expiry date indicated on the package.
Pharmacological effect Imunofan
The preparation has an immunoregulatory, detoxifying and hepatoprotective effect and induces inactivation of free-radical and peroxide compounds.
Testimony Imunofan
- It is used in adults and children older than 2 years for prevention and treatment of immunodeficiency and toxic conditions,
- acute and chronic infectious inflammatory diseases.
Method of use, course and dosage Imunofan
Intranasally. When using the bottle should be kept vertically, with the spray up. Remove the protective cap from the spray bottle. Fill the dosing pump three to four times before the first application by pressing on the wide rim of the sprayer. Insert the sprayer in the bow while the head is in the vertical position. Push the wide rim of the sprayer to the full once. One dose of the drug contains 50 micrograms of imunofan. The daily dose should not exceed 200 μg.
In the complex therapy of acute and chronic infectious and inflammatory diseases accompanied by symptoms of intoxication and immune deficiency, Imunofan is prescribed one dose (50 μg) per nasal passage twice daily, for ten to fifteen days daily.
- Nosology (ICD codes)
- A23
- Brucellosis
- A56.0
- Chlamydia infections of the lower urinary tract
- A56.1
- Chlamydia infections of pelvic organs and other urinary organs
- A60
- Anogenital herpetic virus infection [herpes simplex]
- B00
- Infections caused by herpes simplex virus [herpes simplex]
- B02
- Shingles [herpes zoster]
- B18.0
- Chronic viral hepatitis B with delta agent
- B18.1
- Chronic viral hepatitis B without delta agent
- B18.2
- Chronic viral hepatitis C
- B24
- Human immunodeficiency virus [HIV], unspecified
- B25
- Cytomegalovirus disease
- B38
- Coccidioidomycosis
- B58
- Toxoplasmosis
- B59
- Pneumocystis (B17.3*)
- D84.9
- Immunodeficiency unspecified